Cellectar Biosciences remains a high-risk, pre-revenue biotechnology firm whose long-term viability is tethered to the successful clinical advancement of its proprietary PDC platform.
Price trend, volume and key moving averages
Trailing total returns as of 11/9/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 13, 2026 | -$0.57-9.6% vs -$0.52 | — vs $12M |
Q2 2026 May 14, 2026 | -$1.33+29.4% vs -$1.89 | — vs $8M |
Q2 2026 Mar 4, 2026 | -$0.53+55.5% vs -$1.19 | — vs $13M |
Q4 2025 Nov 13, 2025 | -$1.41+26.2% vs -$1.91 | — vs — |
Subgroup analysis of patients who received Bruton Tyrosine Kinase inhibitor (BTKi) treatment immediately prior to iopofosine I 131 achieved 87.5% ORR, 79.2% MRR and 100% CBR with median DOR of 16 months
Demonstrated Major Response Rate of 79.2%, Overall Response Rate of 87.5%, and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Benchmark CLRB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Cellectar Biosciences, Inc. (CLRB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.25 | $15.29M | -0.68 | — | — | -165.71% | — | |
| $7.53 | $221.24M | -1.76 | -92.81% | -12635.12% | — | — | |
| $235.30 | $34.13B | 21.18 | 9.85% | 27.79% | 25.14% | 1.03% | |
| $7.15 | $297.74M | 21.19 | 10.37% | 20.98% | — | — | |
| $0.89 | $14.89M | -1.98 | -100% | -706.23% | -56.96% | — | |
| $29.87 | $1.99B | -7.59 | -78.63% | -275986.61% | -52.67% | — |
Cellectar Biosciences, Inc. (CLRB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Cellectar Biosciences, Inc. (CLRB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 13, 2026·SEC
Jul 10, 2026·SEC
May 18, 2026·SEC
Get notified when CLRB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Cellectar Biosciences, Inc. (CLRB) stock FAQ — growth, dividends, profitability & financials explained
No. Cellectar Biosciences, Inc. (CLRB) reported a net loss of $22.3M over the trailing twelve months.
Cellectar Biosciences, Inc. (CLRB) had a return on equity (ROE) of -165.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Cellectar Biosciences, Inc. (CLRB) had negative free cash flow of $19.5M over the trailing twelve months.
